New cocktail therapy shows promise for tough lung cancer
NCT ID NCT04716933
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study tested whether adding lenvatinib to standard chemotherapy plus pembrolizumab helps adults from mainland China with advanced nonsquamous non-small cell lung cancer live longer or slow tumor growth. About 200 participants received either the four-drug combo or a placebo version. The goal was to see if the extra drug improves progression-free and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSQUAMOUS NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital ( Site 0120)
Beijing, Beijing Municipality, 100036, China
-
Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)
Urumuqi, Xinjiang, 830000, China
-
Cancer Hospital Chinese Academy of Medical Science ( Site 0117)
Beijing, Beijing Municipality, 100021, China
-
First Affiliated Hospital of The Third Military Medical University ( Site 0118)
Chongqing, Chongqing Municipality, 400038, China
-
Fujian Provincial Cancer Hospital ( Site 0102)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital ( Site 0112)
Zhengzhou, Henan, 450008, China
-
Hubei Cancer Hospital ( Site 0122)
Wuhan, Hubei, 430079, China
-
Jilin Cancer Hospital ( Site 0115)
Changchun, Jilin, 130103, China
-
Peking Union Medical College Hospital ( Site 0108)
Beijing, Beijing Municipality, 100006, China
-
Shanghai Pulmonary Hospital ( Site 0101)
Shanghai, Shanghai Municipality, 200443, China
-
Southern Medical University Nanfang Hospital ( Site 0121)
Guangzhou, Guangdong, 510515, China
-
The First Affiliated Hospital Zhejiang University ( Site 0109)
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)
Wenzhou, Zhejiang, 325000, China
-
The Second Hospital Affiliated to AMU ( Site 0119)
Chongqing, Chongqing Municipality, 400037, China
-
The Third Affiliated Hospital of Harbin Medical University ( Site 0100)
Harbin, Heilongjiang, 150081, China
-
Tianjin Medical University Cancer Institute & Hospital ( Site 0111)
Tianjin, Tianjin Municipality, 300060, China
-
Wuhan Union Hospital ( Site 0123)
Wuhan, Hubei, 430022, China
-
Zhejiang Cancer Hospital ( Site 0113)
Hangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital Fudan University ( Site 0103)
Shanghai, Hunan, 200032, China
Conditions
Explore the condition pages connected to this study.